Skip to main content
. 2002 Jan;9(1):18–28. doi: 10.1101/lm.45802

Figure 4.

Figure 4

(A) Mean trials to criterion on acquisition of the visual-cue discrimination after bilateral infusions of saline or SCH23390 (0.1 and 1 μg) into the prelimbic–infralimbic areas. Because there was no difference between the effects of SCH23390 at 0.1 μg or 1 μg the data were combined into one group for the analyses. SCH23390 at the 0.1- and 1-μg doses did not impair acquisition compared to that of saline infusions. The treatment received on this test is underlined for each group. (B) Mean trials to criterion on the shift to the visual-cue discrimination after saline or infusions of SCH23390 into the prelimbic–infralimbic areas. SCH23390 at the 1-μg dose, but not the 0.1-μg dose, significantly increased the trials to criterion compared to that of saline injections. The treatment received on this test is underlined for each group. SAL, saline; SCH, SCH23390; *, P < 0.05.